No Data
Express News | Repare Therapeutics Announces Agreement With the US National Cancer Institute to Advance the Development of Camonsertib
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Morgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
Repare Therapeutics: Strong Financial Health and Promising Data Catalysts Justify Buy Rating With $10 Price Target
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
No Data
No Data